Dynamic Biosensors and 2bind have signed a technology-service partnership that will enable both companies to further help their customers to accelerate research.
The collaboration will enable 2bind to integrate Dynamic Biosensors’ innovative heliX® system into its service portfolio, giving Dynamic Biosensors another highly experienced partner in the areas of certified services and beta-testing of future technologies.
2bind is a highly respected CRO focused on early-stage drug discovery and antibody development, with more than 10 years’ of market experience. Its customers will benefit from innovative biophysical binding assays based on Dynamic Biosensor’s proprietary switchSENSE® technology, which leverages DNA nanolevers to determine the size and shape of biomolecules.
Thomas Schubert, CEO of 2bind, commented: “2bind has built up a unique portfolio of biophysical methods and assays to offer customized outsourcing solutions in early drug discovery and antibody development. By integrating Dynamic Biosensors’ cutting-edge heliX® biosensor system, we are gaining another powerful tool to meet our customers’ needs and enhance their research capabilities. The innovative switchSENSE® technology features one of the broadest application ranges of any bioanalytical tool. In addition to direct kinetic binding analysis, it provides detection of avidity / cooperative binding and formation of ternary complexes, which are especially useful for programs involving bi-specific antibodies or PROTAC/molecular glue compounds. The heliX® biosensor also enables the monitoring of conformational changes in proteins, induced for example upon ligand binding. These versatile analysis modes will enrich 2bind’s hit validation capabilities in small molecule and antibody discovery programs. 2bind is proud to become a certified service provider for Dynamic Biosensors’ innovative products and we look forward to driving scientific advances through our expertise in biophysics.”
The partnership positions 2bind as a trusted service partner for the switchSENSE® technology and as a development site for beta-testing novel developments aimed at strengthening Dynamic Biosensors’ product portfolio with cutting-edge tools for biomolecular interaction analysis.
Ralf Strasser, COO of Dynamic Biosensors, said: “2bind and Dynamic Biosensors share a strong commitment to helping our customers achieve scientific breakthroughs. This agreement underlines the importance of early drug discovery for our business. The high-quality information offered by switchSENSE® also helps lower the attrition rate for drug candidates in later, more expensive stages of drug development. Partnering with 2bind supports our mission to bring innovative methodologies to the market and to drive the expansion of the heliX® biosensor system by demonstrating its benefits to researchers around the world.”